<DOC>
	<DOCNO>NCT00638703</DOCNO>
	<brief_summary>The main purpose study determine Oxalobacter formigenes effective lower urinary oxalate level patient primary hyperoxaluria .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety OxabactTM Reduction Urinary Oxalate Primary Hyperoxaluria Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<criteria>1 . The subject ( legally acceptable representative ) must give write informed consent ( assent subject ≥ 12 year country specific age appropriate ) . For subject le 18 year age , parent guardian provide inform consent subject provide witness verbal assent 2 . Male female subject ≥ 5 year age 3 . Urinary oxalate excretion &gt; 1.0 mmol/1.73m2/day Baseline 4 . Documentation diagnosis PH I PH II one following : 1 . Liver biopsy confirmation deficient liver specific peroxisomal alanineglyoxylate aminotransferase , ( AGT ) mislocalization AGT peroxisomes mitochondrion ( PH I ) deficient glyoxylate reductase/hydroxypyruvate reductase ( GR/HPR ) activity ( PH II ) 2 . Homozygosity compound heterozygosity know mutation causative gene PH I PH II 3 . Increased glycolate excretion PH I increase Lglycerate excretion PH II 5 . Subjects receive pyridoxine must receive stable dose least 3 month prior entry study must remain stable dose study . Other ( nonpyridoxine naïve ) subject ( e.g . Pyridoxine nonresponder : &lt; 30 % reduction urine oxalate level ) receive pyridoxine study entry must willing refrain initiate pyridoxine study participation . Note : There pyridoxinenaïve subject enrol study . 6 . Renal function define estimate GFR ≥ 50 ml/min normalize 1.73m2 body surface area 1 . Pregnant , lactating , actively menstruate woman woman childbearing potential use adequate contraceptive precaution . Sexually active female , unless surgically sterile least 2 year postmenopausal , must use highly effective contraception ( include oral , transdermal , injectable , implanted contraceptive , IUD , abstinence , use condom sexual partner , sterile sexual partner ) 30 day prior first dose OxabactTM must agree continue use precaution clinical study . Note : A highly effective method birth control define one result low failure rate ( i.e . le 1 % per year ) use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine contraceptive device ( IUDs ) , sexual abstinence , vasectomise partner . 2 . Positive serum pregnancy test . 3 . Participation study investigational product , biologic , device , agent within 30 day prior randomization willing forego form investigational treatment study . 4 . Subjects hemodialysis peritoneal dialysis . 5 . Subjects undergone transplantation ( solid organ bone marrow ) . 6 . Chronic gastrointestinal disease associate enteric hyperoxaluria , e.g . history inflammatory bowel disease , colostomy . Note : For clarity , existence Secondary Hyperoxaluria ( e.g . cystic fibrosis , chronic inflammatory bowel disease , short bowel syndrome and/or deficiency intestinal oxalatedegrading bacteria include ( exclusion criterion ) . 7 . Current systemic ( oral , IM , IV ) antibiotic use receive systemic antibiotic within 14 day study enrolment . 8 . History chronic , recurrent infection require &gt; 2 course antibiotic past 6 month . 9 . History malignancy except basal squamous cell skin cancer excise . 10 . Unable collect 24hour urine sample follow study procedure . 11 . Subjects swallow size 2 capsule . 12 . Presence medical condition Principal Investigator consider likely make subject susceptible adverse effect study treatment unable follow study procedure . 13 . Subjects require immune suppressive therapy ( include prednisone &gt; 10mg daily 2 week ) . 14 . Subjects correctional facility asylums . 15 . Subjects mentally handicap .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hyperoxaluria</keyword>
	<keyword>PH</keyword>
	<keyword>oxalate</keyword>
</DOC>